NCT03742921 2023-12-06
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Celgene
Completed
Clinical Trials
12 trialsNCT03770000 2022-10-28
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Rhizen Pharmaceuticals SA
Phase 1/2 Completed
NCT00426764 2020-02-11
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Phase 2 Completed
NCT01324310 2019-11-25
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT01324323 2019-11-25
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT00106301 2019-11-18
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
Celgene
Phase 2 Completed
NCT00106418 2019-11-18
A Research Study for Patients With Prostate Cancer
Celgene
Phase 2 Completed
NCT00106431 2019-10-30
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Celgene
Phase 2 Completed
NCT00379639 2019-10-30
A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
Celgene
Phase 1 Completed
NCT00106613 2019-10-18
A Research Study for Patients With Metastatic Renal Cell Carcinoma
Celgene
Phase 2 Completed
NCT01456039 2019-02-11
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Celgene
Phase 1/2 Completed
NCT01482962 2018-07-31
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Takeda
Phase 3 Completed